Weeks 13 to 24: full therapeutic effect Once you reach your maintenance dose and have been on it for several weeks, the full appetite-suppressing effects of retatrutide become established

Monitor for: Gastrointestinal symptoms: Nausea or vomiting (occurring in approximately 1520% of patients at therapeutic doses per FDA labeling) Abdominal pain or cramping Diarrhea or constipation Loss of appetite or early satiety Bloating or abdominal distension Hypoglycemia indicators (particularly if you take other diabetes medications): Trembling, shakiness, or sweating Rapid heartbeat or palpitations Dizziness, lightheadedness, or confusion Hunger or irritability Headache or blurred vision Injection site reactions: Bruising, swelling, or hematoma formation Persistent pain or tenderness Redness or warmth suggesting inflammation Hardness or nodule formation under the skin Semaglutide's mechanism involves glucose-dependent insulin secretion, meaning hypoglycemia risk is generally low when used as monotherapy
Avoid repeated freeze/thaw cycles, as these can degrade peptide structure and reduce purity over time
Long-term Digestive Adaptations Over time, the body gets used to not having a gallbladder
Hu P, Li K, Peng XX, Kan Y, Yao TJ, Wang ZY, et al
Wang Y, Li J, Booher RN, et al